Mihaela Georgiana Musat
YOU?
Author Swipe
View article: Measuring what matters to patients: Systematic literature review of patient-reported outcomes assessment and reporting in locally advanced or metastatic urothelial cancer real-world and clinical studies
Measuring what matters to patients: Systematic literature review of patient-reported outcomes assessment and reporting in locally advanced or metastatic urothelial cancer real-world and clinical studies Open
PROs can assist in the tailoring of treatment strategies to improve outcomes and can aid in enhancing communication between patients and healthcare professionals about treatment choice. Our evaluation of PRO reporting quality identified ro…
View article: Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis
Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis Open
This study supports the established clinical benefit of avelumab 1LM across a broad range of patients with la/mUC in routine practice.
View article: Clinicopathological correlations and prognostic insights in osteosarcoma: a retrospective analysis
Clinicopathological correlations and prognostic insights in osteosarcoma: a retrospective analysis Open
Osteosarcoma (OS) is the most prevalent primary bone malignancy, predominantly affecting adolescents and young adults, and presents significant clinical challenges due to its aggressive nature and high potential for metastasis. This retros…
View article: Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis
Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis Open
Aim: To assess rates of no systemic treatment (NST), attrition across lines of therapy, and factors influencing treatment selection in patients with locally advanced or metastatic urothelial cancer (la/mUC). Methods: Systemat…
View article: Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma Open
Aim: The correlation between response and survival has not been well-studied in relapsed or refractory multiple myeloma (RRMM). Materials & methods: A systematic literature review of Medline, Embase and Cochrane databases (20…
View article: EP226/#923 Economic burden in platinum-resistant ovarian cancer
EP226/#923 Economic burden in platinum-resistant ovarian cancer Open
Objectives Introduction Platinum-resistant ovarian cancer (PROC) is associated with a substantial economic burden. An economic SLR was conducted to evaluate the economic burden and cost-effectiveness analyses (CEA) of therapies used in adv…
View article: PCR124 First-Line Treatment Patterns Among Patients With Locally Advanced or Metastatic Urothelial Cancer (la/mUC): A Systematic Literature Review
PCR124 First-Line Treatment Patterns Among Patients With Locally Advanced or Metastatic Urothelial Cancer (la/mUC): A Systematic Literature Review Open
View article: 2022-RA-1133-ESGO Utility values in PROC
2022-RA-1133-ESGO Utility values in PROC Open
View article: HTA34 The Role of the Mainz Severity Score Index (MSSI) on Disease Related-Clinical Events in Patients with Fabry Disease
HTA34 The Role of the Mainz Severity Score Index (MSSI) on Disease Related-Clinical Events in Patients with Fabry Disease Open
View article: HTA48 Minimum Follow-up Time Required for the Detection of the Impact of Treatments on Neuropathic Pain and Gastrointestinal Complaints in Fabry Disease
HTA48 Minimum Follow-up Time Required for the Detection of the Impact of Treatments on Neuropathic Pain and Gastrointestinal Complaints in Fabry Disease Open
View article: HTA6 Evaluation of Health State Utility Values (HSUV) Used in Health Technology Assessment (HTA) Submissions for Rare Diseases
HTA6 Evaluation of Health State Utility Values (HSUV) Used in Health Technology Assessment (HTA) Submissions for Rare Diseases Open
View article: HTA65 The Relationship between Globotriaosylceramide (GB3), Globotriaosylsphingosine (LYSO-GB3) and Disease-Related Clinical Events in Patients with Fabry Disease
HTA65 The Relationship between Globotriaosylceramide (GB3), Globotriaosylsphingosine (LYSO-GB3) and Disease-Related Clinical Events in Patients with Fabry Disease Open
View article: Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma Open
Progression-free survival (PFS) is a common primary endpoint in newly diagnosed multiple myeloma (NDMM). Patients with NDMM typically have longer PFS and are more likely to achieve minimal residual disease (MRD) or complete response (CR) c…
View article: Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR) Open
Mihaela Georgiana Musat,1 Christina Soeun Kwon,1 Elizabeth Masters,2 Slaven Sikirica,3 Debduth B Pijush,3 Anna Forsythe4 1Evidence Generation, Purple Squirrel Economics, a Wholly Owned Subsidiary of Cytel, Inc., Waltham, MA, USA; 2Real Wor…
View article: Cytotoxicity studies, DNA interaction and protein binding of new Al (III), Ga (III) and In (III) complexes with 5‐hydroxyflavone
Cytotoxicity studies, DNA interaction and protein binding of new Al (III), Ga (III) and In (III) complexes with 5‐hydroxyflavone Open
We report the synthesis and characterization of three new complexes of the natural flavonoid 5‐hydroxyflavone (primuletin) and Al (III), Ga (III), In (III), respectively. The physico‐chemical properties and structural features of these thr…